the aid library

LIST OPTIONS

Filter

3763

Living with the times: A mental health and psychosocial support toolkit for older adults during the COVID-19 pandemic
recommended

Inter-Agency Standing Committee IASC (2021) C1

This resource includes posters with key messages for older adults on how to take care of their well-being and how they can provide support to those around them during the COVID-19 pandemic and beyond. It includes instructions for facilitators of mental health and psychosocial support (MHPSS) on how ... more

Download (162)

View PDF (220)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (158)

View PDF (210)

Pediatric oncology nursing practice in Latin America and the Caribbean

Pan American Health Organisation PAHO (2024) C_WHO

One of the main aims of the WHO Global Initiative for Childhood Cancer and the CureAll Americas framework is to strengthen centers of excellence and promote the training of the health workforce, especially pediatric oncology nurses, specialized in nursing care for children and adolescents with cance... more

External Link

Mycetoma: epidemiology, treatment challenges, and progress

Taha, H.; Fahal, A.; Van de Sande, W. Dovepress open access to scientific and medical research (2015) CC

Mycetoma is a specific chronic, granulomatous, inflammatory disease. It usually involves the subcutaneous tissue, most probably after traumatic inoculation of the causative organism. It has a prolonged, progressive, and indolent course, and, if untreated, it ultimately leads to destruction of the de... more

Download (506)

View PDF (1115)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (764)

View PDF (1571)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (209)

View PDF (342)

Innovation in deinstitutionalization: a WHO expert survey

World Health Organization WHO (2014) C_WHO

Based on the survey, five principles for deinstitutionalization were identified: community-based services must be in place; the health workforce must be committed to change; political support at the highest and broadest levels is crucial; timing is key; and additional financial resources are needed.

Download (348)

View PDF (490)

Community Ear & Hearing Health - Volume 9 • Issue 12 (2012)

Community Ear & Hearing Health (2012) C2

This journal is funded by CBM

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (175)

View PDF (234)

Health, rights and drugs - Harm reduction, decriminalization, and zero discrimination for people who use drugs

UNAIDS (Joint United Nations Programme on HIVAIDS) (2019) C2

Download (251)

View PDF (319)

Global clinical data platform for severe acute hepatitis of unknown aetiology in children case report form (CRF)

World Health Organization WHO (2022) C_WHO

Multiple countries are reporting severe acute cases of hepatitis of unknown aetiology in children, in several regions of the world. WHO has developed this clinical case report form (CRF) to support and facilitate reporting of anonymized, patient-level data of acute hepatitis of unknown aetiology.

Download (148)

View PDF (176)

Start Free Stay Free AIDS Free (2017 progress report)

UNAIDS; Unicef; World Health Organization; et al. UNAIDS; Unicef; World Health Organization; et al. (2017) C2

Download (505)

View PDF (724)

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.

Download (241)

View PDF (180)

My Pregnancy (Arabic Version)

Health Service Excecutive HSE Ireland (2021) CC

Download (208)

View PDF (212)

Quick guide to video-supported treatment of tuberculosis (2020)

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Despite being a curable and preventable disease, tuberculosis (TB) remains as one of the major challenges for health systems, globally. Every year, TB affects more than 10 million people and kills more than 1.4 million people. WHO’s Digital Health for the End TB Strategy – an Agenda for Action o... more